Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

Published:2021-01 Issue:1 Volume:8 Page:e34-e44
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Ladetto Marco,Cortelazzo Sergio,Ferrero Simone,Evangelista Andrea,Mian Michael,Tavarozzi Rita,Zanni Manuela,Cavallo Federica,Di Rocco Alice,Stefoni Vittorio,Pagani Chiara,Re Alessandro,Chiappella Annalisa,Balzarotti Monica,Zilioli Vittorio R,Gomes da Silva Maria,Arcaini Luca,Molinari Anna L,Ballerini Filippo,Ferreri Andrés J M,Puccini Benedetta,Benedetti Fabio,Stefani Piero M,Narni Franco,Casaroli Ivana,Stelitano Caterina,Ciccone Giovannino,Vitolo Umberto,Martelli Maurizio

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues;Swerdlow,2008

2. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era;Pérez-Galán;Blood,2011

3. Improvement of overall survival in advanced stage mantle cell lymphoma;Herrmann;J Clin Oncol,2009

4. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Dreyling;Ann Oncol,2014

5. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trial;Scientific Reports;2024-07-23

3. Obinutuzumab vs rituximab for transplant-eligible patients with mantle cell lymphoma;Blood;2024-07-18

4. Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review;JAMA Network Open;2024-06-03

5. Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyond;Leukemia & Lymphoma;2023-10-06